Ainos, Inc. Warrants (AIMDW)

Biotechnology company Ainos reported its Q2 2025 financial results, marking its first commercial revenue through AI Nose platform partnerships and ongoing VELDONA therapy clinical trials, while experiencing increased operating expenses and cash decline.

Ainos Inc., a pharmaceutical company, has received a notice from Nasdaq indicating that its stock price has been below the minimum required bid price for continued listing. The company has been granted a period of 180 days to regain compliance, but if it fails to do so, it may face delisting procedures.